Effects of Formulation Variables on the Particle Size and Drug Encapsulation of Imatinib-Loaded Solid Lipid Nanoparticles

AAPS PharmSciTech

Volumn 17, Issue 3, 2016, Pages 652-662

  Gupta, Biki ^a   Poudel, Bijay Kumar ^a   Pathak, Shiva ^a   Tak, Jin Wook ^a   Lee, Hee Hyun ^a   Jeong, Jee Heon ^a   Choi, Han Gon ^b   Yong, Chul Soon ^a   Kim, Jong Oh ^a  

^a Yeungnam University   (South Korea)

^b Hanyang University   (South Korea)

Author keywords

Box Behnken design; imatinib; Plackett Burman design; response surface methodology; solid lipid nanoparticle

Indexed keywords

IMATINIB; SOLID LIPID NANOPARTICLE; LIPID; NANOPARTICLE;

ARTICLE; BOX BEHNKEN DESIGN; DRUG FORMULATION; EXPERIMENTAL DESIGN; IN VITRO STUDY; NANOENCAPSULATION; PARTICLE SIZE; PH; PLACKETT BURMAN DESIGN; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; ULTRAVIOLET RADIATION; X RAY DIFFRACTION; CHEMISTRY; MEDICINAL CHEMISTRY; METABOLISM; PROCEDURES; SYNTHESIS;

CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; IMATINIB MESYLATE; LIPIDS; NANOPARTICLES; PARTICLE SIZE; X-RAY DIFFRACTION;

EID: 84939824718     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-015-0384-z     Document Type: Article

References (38)

1. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640–53.
2. Al-Hadiya BMH, Bakheit AHH, Abd-Elgalil AA. Imatinib mesylate. In: Brittain HG, editor. Profiles of drug substances, excipients, and related methodology. San Diego: Elsevier Inc.; 2014. p. 265–97.
3. Harde H, Das M, Jain S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin Drug Deliv. 2011;8:1407–24.
4. Gündüz H, Özlü Y, Yalçin S. Process for the preparation of imatinib base. US Patent No. US8252926 B2. 2012.
5. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–77.
6. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165–96.
7. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56:1257–72.
8. Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2:289–300.
9. Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release. 2009;133:238–44.
10. Fonte P, Nogueira T, Gehm C, Ferreira D, Sarmento B. Chitosan-coated solid lipid nanoparticles enhance oral absorption of insulin. Drug Deliv Transl Res. 2011;1:299–308.
11. Lobovkina T, Jacobson GB, Gonzalez-Gonzalez E, Hickerson RP, Leake D, Kaspar RL, et al. In vivo sustained release of siRNA from solid lipid nanoparticles. ACS Nano. 2011;5:9977–83.
12. Montenegro L, Sinico C, Castangia I, Carbone C, Puglisi G. Idebenone-loaded solid lipid nanoparticles for drug delivery to the skin: in vitro evaluation. Int J Pharm. 2012;434:169–74.
13. Shi S, Han L, Deng L, Zhang Y, Shen H, Gong T, et al. Dual drug (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. J Control Release. 2014;194:228–37.
14. Pople PV, Singh KK. Development and evaluation of topical formulation containing solid lipid nanoparticles of vitamin A. AAPS PharmSciTech. 2006;7(4):E63–9.
15. Lionberger RA, Lee SL, Lee L, Raw A, Yu LX. Quality by design: concepts for ANDAs. AAPS J. 2008;10:268–76.
16. Poudel BK, Marasini N, Tran TH, Choi HG, Yong CS, Kim JO. Formulation, characterization and optimization of valsartan self-microemulsifying drug delivery system using statistical design of experiments. Chem Pharm Bull. 2012;60:1409–18.
17. Dejaegher B, Heyden YV. Experimental designs and their recent advances in set-up, data interpretation, and analytical applications. J Pharm Biomed Anal. 2011;56:141–58.
18. Gupta B, Poudel BK, Tran TH, Pradhan R, Cho HJ, Jeong JH, et al. Modulation of pharmacokinetic and cytotoxicity profile of imatinib base by employing optimized nanostructured lipid carriers. Pharm Res. 2015. doi:10.1007/s11095-015-1673-7.
19. Velpandian T, Mathur R, Agarwal NK, Arora B, Kumar L, Gupta SK. Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. J Chromatogr B. 2004;804:431–4.
20. Ramasamy T, Khandasami US, Ruttala H, Shanmugam S. Development of solid lipid nanoparticles enriched hydrogels for topical delivery of anti-fungal agent. Macomol Res. 2012;20:682–92.
21. Wang S, Chen T, Chen R, Hu Y, Chen M, Wang Y. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies. Int J Pharm. 2012;430:238–46.
22. Yuan Q, Han J, Cong W, Ge Y, Ma D, Dai Z, et al. Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity. Int J Nanomedicine. 2014;9:4829–46.
23. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech. 2011;12(1):62–76.
24. Derringer G, Suich R. Simultaneous optimization of several response variables. J Qual Technol. 1980;2:214–9.
25. Selvamuthukumar S, Velmurugan R. Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. Lipids Health Dis. 2012;11:159–66.
26. Lainé AL, Gravier J, Henry M, Sancey L, Béjaud J, Pancani E, et al. Conventional versus stealth lipid nanoparticles: formulation and in vivo fate prediction through FRET monitoring. J Control Release. 2014;188:1–8.
27. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53:283–318.
28. Zhang C, Gu C, Peng F, Liu W, Wan J, Xu H, et al. Preparation and optimization of triptolide-loaded solid lipid nanoparticles for oral delivery with reduced gastric irritation. Molecules. 2013;18:13340–56.
29. Hao J, Fang X, Zhou Y, Wang J, Guo F, Li F, et al. Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design. Int J Nanomedicine. 2011;6:683–92.
30. Shah MK, Madan P, Lin S. Preparation, in vitro evaluation and statistical optimization of carvedilol-loaded solid lipid nanoparticles for lymphatic absorption via oral administration. Pharm Dev Technol. 2014;19:475–85.
31. Zhang X, Liu J, Qiao H, Liu H, Ni J, Zhang W, et al. Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technol. 2010;197:120–8.
32. Sofou S. Radionuclide carriers for targeting of cancer. Int J Nanomedicine. 2008;3:181–99.
33. Tran TH, Ramasamy T, Truong DH, Shin BS, Choi HG, Yong CS, et al. Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells. Pharm Res. 2014;31:1978–88.
34. Zhang XY, Qiao H, Ni JM, Shi YB, Qiang Y. Preparation of isoliquiritigenin-loaded nanostructured lipid carrier and the in vivo evaluation in tumor-bearing mice. Eur J Pharm Sci. 2013;49:411–22.
35. Shen Y, Tang H, Radosz M, Van Kirk E, Murdoch WJ. pH-responsive nanoparticles for cancer drug delivery. In: Jain KK, editor. Drug delivery systems (methods in molecular biology). New Jersey: Humana Press; 2008. p. 183–216.
36. Gao W, Chan J, Farokhzad OC. pH-responsive nanoparticles for drug delivery. Mol Pharm. 2010;7:1913–20.
37. Pradhan R, Kim Y, Chang SW, Kim JO. Preparation and evaluation of once-daily sustained-release coated tablets of tolterodine-L-tartrate. Int J Pharm. 2014;460:205–11.
38. Arora G, Malik K, Singh I, Arora S, Rana V. Formulation and evaluation of controlled release matrix mucoadhesive tablets of domperidone using Salvia plebeian gum. J Adv Pharm Technol Res. 2011;2:163–9.